ANIP ANI PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%
Margins
Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%
Returns
ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $290.78M | $266.04M | $237.46M | $247.06M | $227.81M | $211.37M | $197.12M | $190.57M |
| Cost of revenue | $111.53M | $100.16M | $93.58M | $100.27M | $93.39M | $74.61M | $73.04M | $80.28M |
| Gross profit | $179.25M | $165.89M | $143.88M | $146.79M | $134.42M | $136.76M | $124.08M | $110.29M |
| R&D expense | $13.00M | $14.75M | $10.60M | $12.26M | $12.30M | $16.54M | $10.56M | $16.65M |
| SG&A expense | $94.86M | $91.66M | $73.66M | $82.79M | $76.66M | $81.77M | $76.53M | $69.72M |
| Operating income | $52.37M | $40.46M | $38.89M | $34.77M | $36.24M | $13.89M | $26.19M | -$4.38M |
| Interest expense | $7.59M | $7.50M | $7.55M | $7.96M | $8.28M | $8.22M | $8.11M | $8.80M |
| Pretax income | $49.04M | $37.10M | $40.22M | $31.48M | $33.80M | $10.53M | $19.99M | -$13.76M |
| Income tax | $13.89M | $12.39M | $10.73M | $3.99M | $7.18M | $1.98M | $4.31M | -$3.49M |
| Net income | $35.15M | $24.71M | $29.49M | $27.49M | $26.62M | $8.55M | $15.68M | -$10.28M |
| EBITDA | $71.92M | $60.10M | $59.81M | $57.38M | $58.87M | $37.17M | $49.09M | $18.22M |
| EPS (basic) | 1.54 | 1.09 | 1.31 | — | 1.19 | 0.37 | 0.70 | — |
| EPS (diluted) | 1.51 | 1.05 | 1.28 | — | 1.13 | 0.36 | 0.69 | — |
| Weighted avg. shares (diluted) | 21.68M | 21.91M | 21.54M | — | 21.09M | 20.31M | 20.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $420.76M | $360.21M | $311.18M | $285.58M | $262.61M | $217.83M | $149.80M | $144.86M |
| Receivables | $304.45M | $274.47M | $255.43M | $281.08M | $252.62M | $225.65M | $220.33M | $221.73M |
| Inventory | $136.41M | $143.15M | $143.47M | $143.07M | $146.47M | $138.31M | $137.41M | $136.78M |
| Current assets | $902.82M | $825.43M | $747.08M | $753.12M | $698.40M | $602.63M | $536.29M | $528.46M |
| PP&E, net | $81.55M | $73.22M | $67.11M | $62.48M | $63.56M | $59.25M | $58.18M | $56.86M |
| Goodwill | $62.48M | $62.48M | $62.48M | $62.48M | $62.48M | $60.53M | $60.66M | $59.99M |
| Intangibles | $433.11M | $449.86M | $467.16M | $479.53M | $499.82M | $520.32M | $538.50M | $541.83M |
| Total assets | $1.57B | $1.49B | $1.42B | $1.44B | $1.41B | $1.34B | $1.29B | $1.28B |
| Current liabilities | $328.72M | $283.65M | $239.51M | $278.11M | $270.56M | $236.84M | $201.81M | $194.45M |
| Short-term debt | $23.36M | $21.33M | $19.30M | $17.27M | $15.24M | $13.22M | $11.19M | $9.17M |
| Long-term debt | $274.31M | $280.15M | $286.00M | $291.84M | $297.68M | $301.48M | $305.29M | $309.11M |
| Total debt | $297.68M | $301.48M | $305.29M | $309.11M | $312.92M | $314.70M | $316.49M | $318.28M |
| Total liabilities | $930.55M | $896.90M | $859.67M | $899.65M | $902.34M | $881.39M | $848.96M | $855.94M |
| Shareholders' equity | $637.11M | $597.21M | $562.30M | $540.72M | $505.82M | $436.76M | $418.62M | $403.68M |
| Net debt | -$123.08M | -$58.73M | -$5.88M | $23.52M | $50.31M | $96.87M | $166.69M | $173.42M |
| Shares outstanding | — | — | — | 22.49M | — | — | — | 21.11M |
| Cash flow statement | ||||||||
| Operating cash flow | $83.79M | $56.67M | $58.38M | $30.37M | $44.05M | $75.81M | $34.99M | $15.86M |
| Capital expenditure | $13.50M | $3.05M | $6.07M | $1.24M | $6.10M | $4.01M | $2.47M | $2.39M |
| Free cash flow | $70.28M | $53.62M | $52.30M | $29.12M | $37.95M | $71.80M | $32.52M | $13.47M |
| Investing cash flow | -$13.50M | -$3.05M | -$11.32M | -$1.40M | -$6.16M | -$6.91M | -$19.85M | -$10.68M |
| Financing cash flow | -$9.83M | -$4.65M | -$21.62M | -$4.64M | $6.34M | -$1.75M | -$9.91M | -$4.91M |
| Depreciation & amortization | $19.55M | $19.64M | $20.92M | $22.61M | $22.63M | $23.28M | $22.89M | $22.60M |
| Stock-based compensation | $11.63M | $11.41M | $10.19M | $9.77M | $9.69M | $9.60M | $8.87M | $7.06M |
| Dividends paid | $0 | $0 | $0 | $0 | $344,000 | $407,000 | $406,000 | $406,000 |
| Share buybacks | -$13.58M | $813,000 | $19.75M | $611,000 | $1.04M | $551,000 | $10.00M | $318,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.